Home
  • Clinical Trials
  • Partnerships
  • Contact Us
  • News & Resources
  • Careers
  • About Us
    • Management Team
    • Board of Directors
    • Scientific and Clinical Advisory Boards
    • Commercial Advisory Board
  • Our Focus
    • Infectious Disease
    • Oncology
  • Our Product
  • Our Pipeline
    • Prophylactic
    • Therapeutic
    • Clinical Trials
    • Publications
    • Early/Expanded Access Policy
  • Our Science
  • Investors
    • Press Releases
    • Events and Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • About Us
    • Management Team
    • Board of Directors
    • Scientific and Clinical Advisory Boards
    • Commercial Advisory Board
  • Our Focus
    • Infectious Diseases
    • Oncology
  • Our Pipeline
    • Prophylactic
    • Therapeutic
    • Clinical Trials
    • Publications
    • Early/Expanded Access Policy
  • Our Product
  • Our Science and Technology
  • News and Resources
    • News
    • Posters
    • Publications
    • Videos
  • Investors
    • Press Releases
    • Company Information
    • Corporate Governance
    • Events and Presentations
    • SEC Filings
    • Stock Information
  • Careers
  • Partnerships
  • Contact Us
Search our website

Efficacy and Safety of a 3-antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation

October 1, 2020 |

Efficacy and Safety of a 3-antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation
Clinical Infectious Diseases
October 2020

View More

March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results


February 23, 2023

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat


February 15, 2023

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B


December 8, 2022

VBI Vaccines Announces Health Canada Approval for PreHevbrioâ„¢ for the Prevention of Hepatitis B in Adults


Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top
Navigate
  • About Us
  • Our Focus
  • Our Science and Technology
  • Our Pipeline
  • Investors
  • Clinical Trials
  • Contact Us
About Us
  • Management Team
  • Board of Directors
  • Scientific and Clinical Advisory Boards
  • Commercial Advisory Board
  • Partnerships
  • News and Resources
  • Careers
Connect With Us
  • Twitter Icon
  • Facebook Icon
  • YouTube Icon
  • LinkedIn Icon
VBI Logo Home

© 2023 VBI Vaccines Inc. All rights reserved.

  • Privacy Policy
  • Cookies Policy
  • Terms of Use
  • Site Map
  • Contact Us